Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma

Blood

Volumn 112, Issue 9, 2008, Pages 3914-3915

  Moreau, Philippe ^a   Garban, Frédéric ^a   Attal, Michel ^a   Michallet, Mauricette ^a   Marit, Gérald ^a   Hulin, Cyrille ^a   Benboubker, Lotfi ^a   Doyen, Chantai ^a   Mohty, Mohamad ^a   Yakoub Agha, Ibrahim ^a   Leyvraz, Serge ^a   Casassus, Philippe ^a   Avet Loiseau, Hervé ^a   Garderet, Laurent ^a   Mathiot, Claire ^a   Harousseau, Jean Luc ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BUSULFAN; FLUDARABINE; THYMOCYTE ANTIBODY;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME ABERRATION; DRUG MEGADOSE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; LETTER; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REDUCED INTENSITY CONDITIONING; TREATMENT RESPONSE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; RISK FACTOR; STEM CELL TRANSPLANTATION;

DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MULTIPLE MYELOMA; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 55749090051     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-168823     Document Type: Letter

References (9)

1. Kröger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755-760.
2. Maloney D, Molina A, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447-3454.
3. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474-3480.
4. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-1120.
5. Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reducedintensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112:3591-3593.
6. Lokhorst H. No RIC in high-risk myeloma? Blood. 2006;107:3420-3421.
7. Crawley C, Iacobelli S, Björkstrand B, et al. Reduced intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109:3588-3594.
8. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoieticcell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
9. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434-2441.